Severe Encephalopathy, Lactic Acidosis, Vegetative Instability and Neuropathy with 5-Fluorouracil Treatment – Pyrimidine Degradation Defect or Beriberi? by Rosen, A. et al.
Case Rep Oncol 2011;4:371–376 
DOI: 10.1159/000328803 
Published online: 
August 10, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online
version of the article only. Distribution for non-commercial purposes only. 
 
 
Dr. med. Alex Rosen    Clinic for Pediatric Oncology, Hematology and Immunology 
University Children Hospital Düsseldorf 
Moorenstrasse 5 
DE–40225 Düsseldorf (Germany) 
Tel. +49 178 476 8426, E-Mail alexander.rosen @ med.uni-duesseldorf.de 
 
371
   
Severe Encephalopathy, Lactic 
Acidosis, Vegetative Instability 
and Neuropathy with 
5-Fluorouracil Treatment – 
Pyrimidine Degradation Defect 
or Beriberi? 
A. Rosena    A. van Kuilenburgc    B. Assmanna    M. Kuhlenb    
A. Borkhardtb  
Departments of aGeneral Pediatrics, and bPediatric Oncology, Hematology and 
Immunology, University Children Hospital Düsseldorf, Düsseldorf, Germany; 
cLaboratory Genetic Metabolic Diseases, Academic Medical Center of the 
University of Amsterdam, Amsterdam, The Netherlands 
 
 
Key Words 
Beriberi · 5-FU · Pyrimidine degradation defect 
 
Abstract 
We present the case of a 19-year-old female with nasopharyngeal carcinoma, who 
received two courses of chemotherapy with 5-fluorouracil (5-FU) in combination with 
folic acid and cisplatin. Upon developing esophageal strictures in the course of her 
radiotherapy, she required total parenteral nutrition. In the course of therapy, the patient 
developed severe multisystem failure with encephalopathy, lactic acidosis, vegetative 
instability and neuropathy. The treatment with 5-FU can lead to severe toxicity due to 
enzyme deficiencies in the degradation of pyrimidines, but it can also lead to thiamine 
deficiency with the classic symptoms of beriberi. Beriberi is a rare disorder, usually 
attributed to malnutrition or alcoholism. 5-FU has been shown to induce thiamine 
depletion. Reduced food intake or total parenteral nutrition devoid of vitamin 
supplements may aggravate symptoms. We were unable to find a genetic cause for 
increased 5-FU toxicity in our patient, ruling out deficiencies of dihydropyrimidine 
dehydrogenase, dihydropyrimidinase or β-ureidopropionase and double-strand break 
repair deficits. We come to the conclusion that, even without any definable enzyme 
deficiency, treatment with 5-FU can lead to high toxicity due to thiamine deficiency if 
vitamin supplementation is not undertaken. 
 Case Rep Oncol 2011;4:371–376 
DOI: 10.1159/000328803 
Published online: 
August 10, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–6575 
www.karger.com/cro   
 
 
 
372
Introduction 
Vitamin B1, or thiamine, is an important dietary factor for the human metabolism. The 
phosphorylated form, thiamine pyrophosphate (TPP), serves as cofactor for several vital 
metabolic processes, most importantly the conversion of pyruvate to acetyl coenzyme A 
and the conversion of α-ketoglutarate to succinyl coenzyme A in the citric acid cycle and 
several chemical reactions in the pentose-phosphate pathway. The human body requires 
between 0.3 and 1.7 mg of vitamin B1 per day, depending on age and gender. Vitamin B1 
is present in yeast, soy products, legumes, cereals and meat. 
Without regular intake of this vitamin, energy metabolism in organs such as the brain 
or the heart is compromised, leading to symptoms of beriberi. ‘Beriberi’ is a Singhalese 
term, roughly translating to ‘I cannot, I cannot’, which aptly describes the loss of body 
functions in the course of the disease. The symptoms of beriberi are divided into two 
forms, which can be seen in combination or isolated from each other: 
(1) ‘Dry beriberi’, consisting of peripheral neuropathy and Wernicke’s encephalopathy, 
a combination of ophthalmoparesis, diplopia, horizontal nystagmus, reflex disorders, 
confusion, disorientation, apathy, somnolence, ataxia, dysdiadochokinesia, dysarthria, 
dysphagia, insomnia, psychosis and vegetative symptoms such as hypotension, 
hypothermia or hyperhydrosis. 
(2) ‘Wet beriberi’, consisting of cardiomyopathy, heart failure, cardiomegaly, 
peripheral edemas and tachycardia. 
Vitamin B1 deficiency is a rare disorder, usually observed in patients with alcoholism 
or with severe malnutrition. There are, however, cases of iatrogenic vitamin B1 deficiency, 
where long-term treatment with total parenteral nutrition (TPN) devoid of thiamine 
induced symptoms of beriberi in pediatric populations [1–3]. Four general causes can be 
identified, which can lead to symptoms of thiamine deficiency either by themselves or in 
combination: 
(1) Reduced thiamine intake (due to fasting, alcoholism, general malnutrition, 
inactivation of thiamine in food by cooking or through inactivating factors contained in 
certain fish, tannins or coffee, or iatrogenic as described above). 
(2) Reduced thiamine absorption (short bowel syndrome, celiac disease, chronic 
inflammatory bowel disease). 
(3) Increased thiamine excretion (diarrhea, dialysis, diuretic treatment). 
(4) Increased thiamine metabolism (pregnancy, fever, activity, iatrogenic). 
Patients receiving 5-fluorouracil (5-FU) have shown to have an increased thiamine 
metabolism and subsequently low thiamine levels [4, 5]. Several reports describe cases of 
increased 5-FU toxicity due to enzyme mutations in the pyrimidine degradation pathway. 
The most frequent cause is a defect of dihydropyrimidine dehydrogenase (DPD), less 
common causes include defects of the enzyme dihydropyrimidinase and β-
ureidopropionase [6–8]. Case Rep Oncol 2011;4:371–376 
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Case Presentation 
A 19-year-old female Caucasian patient was diagnosed with Hodgkin’s lymphoma in December 
2004. She was treated with 2 blocks of OPPA (vincristine, procarbazine, prednisone and doxorubicin), 2 
blocks of COPP (cyclophosphamide, vincristine, procarbazine and prednisone) and consolidating 
radiotherapy with a total dose of 19.8 Gy until May 2005. After a good recovery and uneventful check-
ups from 2005 until 2009, she was diagnosed with a nasopharyngeal carcinoma including cervical lymph 
node metastases in May 2009. 
Starting in June 2009, we began a chemotherapy treatment according to the NPC-2003-GPOH 
multicentric study for the treatment of nasopharyngeal carcinoma in children and adolescents 
(nasopharyngeal carcinoma trial 2003 of the German Society for Pediatric Oncology and Hematology). 
The initial treatment in this protocol consists of 3 blocks of cisplatin 100 mg/m
2 on day 1 and 5-FU 
1,000 mg/m
2/day for 5 consecutive days as well as 6 doses of folic acid 25 mg/m
2 every 6 h [9]. After the 
first 5-day course of this combination, the patient developed massive mucositis, peripheral edemas, 
paresthesia and electrolyte imbalances and had to be hospitalized for 3 weeks until recovery. 
The second course of chemotherapy was started in July 2009. In the beginning of August, 2 weeks 
after the end of the second block of chemotherapy, our patient again developed severe symptoms of 
even more pronounced toxicity: esophageal strictures, massive mucositis, peripheral edemas, 
myelosuppression, electrolyte imbalances, lactic acidosis, renal insufficiency, hepatopathy with 
hyperbilirubinemia and coagulation deficits, hypoalbuminemia with ascites, pericardial and pleural 
effusion as well as a complex neuropathy with hallucinations, reduced vision, miosis, ptosis, slow pupil 
reactions, a reduced state of consciousness, slurred speech, a vegetative crisis with problems to control 
blood pressure and body temperature, polyradiculitis, peripheral loss of sensibility in the lower legs and 
paresthesia of both hands and feet. 
We suspected encephalitis or an antineuronal autoimmune process and began treatment with 
intravenous acyclovir, immunoglobulins and a substitution of sodium bicarbonate and electrolytes. 
Additionally, the patient also received thiamine infusions for treating a suspected thiamine deficiency. 
The blood results later revealed a concentration of 18.1 μg/l TPP, normal values ranging from 28.0 to 
85.0. The patient showed signs of improvement within hours after this multimodal approach and 
recovered within several days. 
Due to these complications, we performed extensive work-up: cranial MRIs as well as an EEG 
showed no pathological findings. Laboratory tests of the cerebrospinal fluid showed elevated lactate and 
protein, but no growth of bacteria, normal numbers of red and white blood cells and no viruses in the 
standard polymerase chain reaction tests. We were also able to rule out paraneoplastic reactions with 
antineuronal antibodies (Yo, Hu, Ri, Ma1, Ma2, CV2, amphysin). Due to the close proximity of the 
symptom onset after 5-FU treatment, we suspected a defect in the metabolism of pyrimidines. A normal 
activity of DPD was detected in the peripheral blood mononuclear cells, thus ruling out DPD deficiency 
(8.0 nmol/mg/h compared to 9.9 ± 2.8 nmol/mg/h observed in controls). A complete deficiency of 
dihydropyrimidinase or β-ureidopropionase was ruled out by normal results in the analysis of 
pyrimidine degradation metabolites in urine samples (dihydrouracil <4 μmol/l, dihydrothymine 
<1 μmol/l, N-C-β-alanine 7 μmol/l, N-C-β-aminoisobutyric acid 1 μmol/l, uracil 6 μmol/l, thymine <0.4 
μmol/l, 5-hydroxymethyluracil <0.5 μmol/l). Finally, skin fibroblast cultures revealed no double-strand 
break repair deficits or abnormalities in the flux analysis of radioactively labelled deoxyuridine and 5-
fluoro-2c-deoxyuridine. We were thus unable to find a genetic cause for increased 5-FU toxicity in our 
patient. 
After this episode, we decided not to administer 5-FU again and opted for a combination of 
epirubicin, paclitaxel and cisplatin for the third course of chemotherapy in August 2009. This course 
was tolerated much better than the previous two and in September of 2009, we were able to begin 
adjuvant radiation therapy, which was also well tolerated. The patient’s esophageal strictures were, 
however, further exacerbated by radiation therapy. We performed endoscopic dilatation of the 
esophagus and provided the patient with TPN during the weeks of radiation therapy, as she was not able 
to take in food orally. For the first 6 weeks of intravenous alimentation, the patient also received vitamin 
supplementation with both fat- and water-soluble vitamins, including vitamin B1. After a second 
dilatation of the esophagus in October 2009, the patient again required TPN for a period of 11 days. 
This time, however, vitamin supplements were not added. After the end of the 6-week course of 
radiation, the patient was able to take in food orally again and was discharged from the hospital. Case Rep Oncol 2011;4:371–376 
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One week after the end of radiotherapy, she was admitted to the oncology ward again due to 
radiation-induced laryngitis. She had not been able to take in solid foods for some days and had lost 1.6 
kg over the course of 5 days. While on our ward, she again developed neurologic symptoms, especially 
reduced vigilance and drowsiness and began to vomit uncontrollably. Laboratory tests showed an 
acidosis with lactate of 6.31 mmol/l (normal value <2.20). This time, we immediately suspected a 
thiamine deficiency and administered intravenous thiamine at a dosage of 100 mg over the course of 
1 h. Laboratory tests later confirmed this suspicion, showing a TPP in the EDTA blood drawn before 
thiamine substitution of 8.1 μg/l (normal values 28.0–85.0). 
The patient initially improved neurologically, but became unconscious again after about half an 
hour, with a blood sugar of 28 mg/dl (normal values 60–100). After an infusion of glucose solution 
(50%) and stopping the thiamine infusion, the patient improved rapidly with normalization of 
laboratory findings and neurological status. Over the course of the next 5 days, we continued low-dose 
thiamine substitution under close surveillance of the blood sugar and saw a continuous improvement of 
the patient’s condition. She began taking solid foods again and was prescribed oral multivitamin 
supplementation. Until today, similar episodes of symptomatic thiamine deficiency have not occurred 
again. The patient is currently living in remission and is doing remarkably well. 
Discussion 
In retrospect, it can be confirmed that our patient developed the classic symptoms of 
thiamine deficiency (beriberi) as a result of 5-FU toxicity and hypoalimentation with 
vitamin B1. 5-FU has been shown to aggravate or even induce thiamine deficits by 
increasing the cellular thiamine metabolism [10]. Studies were able to demonstrate 
thiamine deficiency as well as decreased activity of the thiamine-dependent enzyme 
transketolase after treatment with 5-FU [4, 5, 11]. Before the first episode of beriberi in 
August 2009, no thiamine levels were determined, but blood tests undertaken after the 
onset of symptoms showed low TPP, suggesting thiamine depletion during the course of 
chemotherapy. Despite successful treatment of the complications by a multimodal 
approach which included thiamine infusion, we were at that point not able to exactly 
determine the cause of the clinical symptoms. 
A genetic and/or biochemical explanation for the increased toxicity of 5-FU in our 
patient was not found. Patients with a deficit in the metabolism of pyrimidines frequently 
experience increased toxicity after 5-FU treatment [8, 12]. In our patient, extensive 
biochemical and genetic work-up did not reveal any known defect in the pyrimidine 
pathway indicating the existence of other, yet unknown reasons for this severe spectrum 
of side effects. 
After developing esophageal strictures, which limited the oral intake of food and led to 
a hypoalimentation with vitamin B1, the patient developed a second episode of thiamine 
deficiency. This time, the symptoms were immediately attributed to a possible thiamine 
deficiency and correctly treated with intravenous infusion of thiamine. However, due to 
the depleted thiamine levels, the substitution of thiamine induced a state of hypoglycemia. 
‘The phenomenon of post-i.v. thiamine hypoglycemia is observed not infrequently in (…) 
thiamine deficiency’ [13]. 
There are several lessons to be learned from this case: 
(1) The combination of lactic acidosis, heart failure, central and peripheral neuropathy 
are highly suggestive of a thiamine deficiency in the setting of an unbalanced diet and/or 
aggressive medication. Case Rep Oncol 2011;4:371–376 
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(2) When administering 5-FU to patients, thiamine levels should be monitored and 
thiamine supplemented upon signs of deficiency. 
(3) Long-term TPN should always contain vitamin supplementation. 
(4) Thiamine supplementation in patients with extensive deficiencies can induce 
hypoglycemia and should therefore be accompanied by glucose-infusions. 
(5) Even without genetic defects of pyrimidine degradation, 5-FU treatment can cause 
exceptional toxicity which may be the result of thiamine deficiency. 
In conclusion, the treatment of cancer patients with 5-FU can lead to thiamine 
deficiency with the classic symptoms of beriberi and may be aggravated by reduced oral 
food intake or TPN devoid of vitamin supplementation. According to a literature review, 
thiamine deficiency in patients receiving TPN or having been treated with 5-FU is not 
uncommon, yet probably underdiagnosed [14, 15]. Knowledge of this important side 
effect of 5-FU treatment may help to prevent severe complications in future patients. 
Testing for genetic defects in the metabolism of pyrimidines should be undertaken before 
starting the treatment. However, clinicians should be alert for the development of severe 
thiamine deficiency even if no genetic defect in the pyrimidine degradation pathway can 
be documented. 
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